Mineralys Therapeutics, Inc.(MLYS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MLYS Mineralys Therapeutics, Inc.

盘前交易 07-10 05:25:12 EDT

28.96

-1.44

-4.74%

最高30.88	最低28.60	成交量126.61万
今开30.30	昨收30.40	日振幅7.52%
总市值25.53亿	流通市值19.12亿	总股本8,816万
成交额3,696万	换手率1.92%	流通股本6,603万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":28.96,"timestamp":1783627200000,"preClose":30.4,"halted":0,"volume":1266117,"delay":0,"changeRate":-0.047368421052631504,"floatShares":66025800,"shares":88158500,"eps":-2.021721,"marketStatus":"盘前交易","change":-1.44,"latestTime":"07-10 05:25:12 EDT","open":30.3,"high":30.88,"low":28.595,"amount":36960431,"amplitude":0.075164,"askPrice":29.61,"askSize":100,"bidPrice":28.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.021721,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783690200000},"marketStatusCode":1,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":28.96,"postHourTrading":{"tag":"盘后","latestPrice":28.96,"preClose":28.96,"latestTime":"16:10 EDT","volume":16043,"amount":464605.28,"timestamp":1783627805080,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.053010258262939,"impliedVol":0.8944,"impliedVolPercentile":0.524},"requestUrl":"/m/hq/s/MLYS","defaultTab":"news","newsList":[{"id":"1137231932","title":"Mineralys Therapeutics将以2亿美元首付款及最高1亿美元里程碑付款回购Lorundrostat特许权使用费义务","url":"https://stock-news.laohu8.com/highlight/detail?id=1137231932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137231932?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:01","pubTimestamp":1780480876,"startTime":"0","endTime":"0","summary":"生物技术公司Mineralys Therapeutics宣布，将回购其核心在研药物Lorundrostat相关的特许权使用费义务。根据协议条款，该公司需支付2亿美元的首付款，并可能根据未来研发及商业里程碑的实现情况，额外支付最高达1亿美元的费用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160218869","title":"Mineralys Therapeutics 宣布回购田边许可协议中的特许权使用费义务并同步进行融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1160218869","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160218869?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:00","pubTimestamp":1780480828,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics 近日宣布，已成功回购其与田边（Tanabe）许可协议项下的特许权使用费义务。与此同时，公司还完成了一项同步的融资安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109149162","title":"Mineralys Therapeutics：Lorundrostat在3期Launch-Htn试验中显著降低慢性肾病患者血压","url":"https://stock-news.laohu8.com/highlight/detail?id=1109149162","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109149162?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154117,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. 宣布，其在研药物Lorundrostat于针对慢性肾病合并高血压患者的3期Launch-Htn临床试验中，展现出显著的血压降低效果。该试验数据为Lorundrostat在控制这一患者群体血压方面的潜力提供了有力支持。Lorundrostat作为一种新型治疗选择，其积极的3期结果可能为患者带来新的希望。公司表示，详细的试验数据将在未来的医学会议上公布，并计划与监管机构讨论后续的申报路径。这一进展对Mineralys Therapeutics, Inc.而言是一个重要的里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198381190","title":"Mineralys Therapeutics试验显示：Lorundrostat显著降低尿白蛋白与肌酐比值","url":"https://stock-news.laohu8.com/highlight/detail?id=1198381190","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198381190?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154115,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. 公布的一项试验数据显示，其候选药物Lorundrostat在降低尿白蛋白与肌酐比值（UACR）方面取得了显著成效。这一关键生物标志物的改善，对于评估肾脏健康，特别是在高血压相关肾损伤领域，具有重要的临床意义。试验结果进一步支持了该药物在靶向治疗中的潜在价值，为后续开发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123865097","title":"Mineralys Therapeutics在ESH 2026会议上公布Lorundrostat针对高血压合并慢性肾病患者的3期LAUNCH-HTN试验新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123865097","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123865097?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154115,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics公司在2026年欧洲高血压与心血管保护会议（ESH 2026）上，公布了其候选药物lorundrostat针对高血压合并慢性肾病患者的三期LAUNCH-HTN临床试验的新数据。这项关键研究旨在评估该药物在这一患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113856617","title":"Mineralys Therapeutics：Lorundrostat在伴或不伴慢性肾病的参与者中展现为期12周的优良安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1113856617","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113856617?lang=zh_cn&edition=full","pubTime":"2026-05-30 23:15","pubTimestamp":1780154112,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics公司宣布，其研究性药物Lorundrostat在为期12周的临床试验中，于伴有或不伴有慢性肾病的参与者群体内均表现出良好的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124459809","title":"Mineralys Therapeutics公布Lorundrostat三期LAUNCH-HTN试验新数据，将于第35届欧洲高血压与心血管保护会议(ESH 2026)展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1124459809","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124459809?lang=zh_cn&edition=full","pubTime":"2026-05-19 04:06","pubTimestamp":1779134782,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. 宣布，其候选药物lorundrostat的三期临床试验LAUNCH-HTN所获得的新数据，已被选入将于2026年举行的第35届欧洲高血压与心血管保护会议(ESH 2026)进行展示。\n这一进展标志着该药物在治疗高血压领域的临床开发取得了重要里程碑。LAUNCH-HTN试验旨在评估lorundrostat在难治性高血压患者中的疗效与安全性，其数据结果备受医学界关注。\n在ESH 2026这一国际顶尖学术平台上公布新数据，将为全球心血管专家提供深入了解lorundrostat潜力的机会，并可能影响其未来的监管审批路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193531299","title":"Mineralys Therapeutics高血压药物Lorundrostat获FDA受理 审评截止日期定为2026年12月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1193531299","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193531299?lang=zh_cn&edition=full","pubTime":"2026-05-07 04:29","pubTimestamp":1778099358,"startTime":"0","endTime":"0","summary":"生物制药公司Mineralys Therapeutics宣布，其针对高血压治疗的新药Lorundrostat的新药申请已获得美国食品药品监督管理局正式受理。根据FDA的审评时间表，该药物的处方药用户付费法案目标审评日期确定为2026年12月22日。此次NDA获受理标志着Lorundrostat在高血压治疗领域的研发进程取得重要阶段性成果。FDA的受理决定意味着该申请资料已通过初步审查，并进入实质性审评阶段。作为Mineralys Therapeutics的核心研发项目，Lorundrostat是一种用于治疗高血压的创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190732479","title":"Mineralys Therapeutics公司Lorundrostat新药申请获FDA指定PDUFA目标行动日期为2026年12月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1190732479","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190732479?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:31","pubTimestamp":1773088285,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc.宣布，美国食品药品监督管理局（FDA）已为其候选药物Lorundrostat的新药申请（NDA）指定了处方药用户费用法案（PDUFA）目标行动日期，定为2026年12月22日。\n该日期标志着FDA完成对Lorundrostat NDA审查的目标时间点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146807380","title":"Mineralys Therapeutics宣布FDA受理Lorundrostat治疗成人高血压新药申请及Explore-Osa试验关键结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1146807380","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146807380?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:31","pubTimestamp":1773088283,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc.（简称Mineralys）宣布，其用于治疗成人高血压的药物Lorundrostat的新药申请（NDA）已获得美国食品药品监督管理局（FDA）的正式受理。同时，该公司还公布了Explore-Osa试验的顶线结果，为该药物的临床数据提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613970758","title":"Mineralys Therapeutics, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613970758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613970758?lang=zh_cn&edition=full","pubTime":"2026-02-24 02:58","pubTimestamp":1771873087,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日02时58分，Mineralys Therapeutics, Inc.股票出现异动，股价急速拉升5.02%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。Mineralys Therapeutics, Inc.公司简介：Mineralys Therapeutics Inc是一家临床阶段的生物制药公司，专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602240258079541b103&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602240258079541b103&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLYS","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274596","title":"美股异动 | 发布高血压药物研究的积极结果 Mineralys Therapeutics(MLYS.US)暴涨超53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274596","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274596?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:32","pubTimestamp":1741620734,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，Mineralys Therapeutics(MLYS.US)逆势暴涨超53%，报16.25美元。消息面上，该公司周一报告了其Lorundrostat药物候选治疗不受控制或耐药性高血压的两项关键研究的积极初步结果。Mineralys表示其三期 Launch-HTN 和二期 Advance-HTN 研究在预先规定的主要疗效终点上达到了统计学显著性，并且具有临床意义，同时显示出良好的安全性和耐受性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518785132","title":"Mineralys Therapeutics, Inc.盘中异动 快速拉升34.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518785132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518785132?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613494,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Mineralys Therapeutics, Inc.股票出现波动，股价大幅拉升34.03%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为1825.42%、384.06%、45.95%，振幅较大的相关个股有Xencor, Inc.、Seer, Inc.、Y-Mabs Therapeutics, Inc.，振幅分别为99.13%、98.72%、94.67%。Mineralys Therapeutics, Inc.公司简介：Mineralys Therapeutics Inc是一家临床阶段的生物制药公司，专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213134a26a2478&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213134a26a2478&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLYS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162530","title":"Mineralys Therapeutics, Inc.盘中异动 早盘股价大涨5.19%报10.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162530?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:52","pubTimestamp":1741276353,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时52分，Mineralys Therapeutics, Inc.股票出现异动，股价快速拉升5.19%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.55%。Mineralys Therapeutics, Inc.公司简介：Mineralys Therapeutics Inc是一家临床阶段的生物制药公司，专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306235234989ec420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306235234989ec420&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514384045","title":"Mineralys Therapeutics, Inc.盘中异动 早盘快速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514384045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514384045?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:54","pubTimestamp":1740671642,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时54分，Mineralys Therapeutics, Inc.股票出现波动，股价急速上涨5.06%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.74%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Heron Therapeutics, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1427.40%、228.24%、108.52%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation，振幅分别为86.14%、47.79%、45.45%。Mineralys Therapeutics, Inc.公司简介：Mineralys Therapeutics Inc是一家临床阶段的生物制药公司，专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227235403abdf8352&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227235403abdf8352&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514025851","title":"Mineralys Therapeutics, Inc.盘中异动 早盘急速拉升5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514025851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514025851?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:02","pubTimestamp":1740582129,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时02分，Mineralys Therapeutics, Inc.股票出现波动，股价大幅上涨5.25%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为4630.96%、159.46%、142.50%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.，振幅分别为155.93%、39.47%、29.31%。Mineralys Therapeutics, Inc.公司简介：Mineralys Therapeutics Inc是一家临床阶段的生物制药公司，专注于开发针对由异常升高的醛固酮引起的疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226230209a254fe07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226230209a254fe07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512601431","title":"Mineralys Therapeutics, Inc.盘中异动 股价大跌5.27%报9.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512601431","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512601431?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:09","pubTimestamp":1739898549,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日01时09分，Mineralys Therapeutics, Inc.股票出现异动，股价急速下挫5.27%。Mineralys Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Ocean Biomedical Inc C/Wts 14/02/2028 、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为496.41%、184.76%、155.32%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Mineralys Therapeutics, Inc.公司简介：Mineralys Therapeutics Inc 是一家临床阶段的生物制药公司，专注于开发药物以治疗醛固酮异常升高引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219010910abd3d042&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219010910abd3d042&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MLYS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511667025","title":"Mineralys Therapeutics, Inc.2024财年实现净利润-1.78亿美元，同比减少147.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511667025","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511667025?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:01","pubTimestamp":1739635282,"startTime":"0","endTime":"0","summary":"2月16日，Mineralys Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.78亿美元，同比减少147.57%；其中营业收入为0.00美元，每股基本收益为-3.66美元。机构评级：截至2025年2月16日，当前有7家机构对Mineralys Therapeutics, Inc.目标价做出预测，其中目标均价为32.00美元，其中最低目标价为24.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000144a24729ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000144a24729ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511506573","title":"高盛：维持Mineralys Therapeutics(MLYS.US)评级，由买入调整至买入评级, 目标价由28.00美元调整至24.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511506573","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511506573?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:38","pubTimestamp":1739468289,"startTime":"0","endTime":"0","summary":"高盛：维持Mineralys Therapeutics(MLYS.US)评级，由买入调整至买入评级, 目标价由28.00美元调整至24.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14013848150609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MLYS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152728977","title":"Mineralys Therapeutics 第四季度每股收益(0.98)美元，超出(1.04)美元预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1152728977","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152728977?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:06","pubTimestamp":1739361974,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  报告的季度每股亏损为美元，这比分析师普遍预期的美元高出5.77%。与去年同期每股亏损美元相比，这下降了60.66%。以上内容来自Benzinga Earnings专栏，原文如下：Mineralys $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 5.77 percent. This is a 60.66 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MLYS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com;www.ir.mineralystx.com","stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":0.1977},{"period":"3month","weight":0.0879},{"period":"6month","weight":-0.1322},{"period":"1year","weight":1.0153},{"period":"ytd","weight":-0.202}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mineralys Therapeutics, Inc.最初成立于2019年5月31日，是特拉华州的一家公司。该公司是一家临床阶段生物制药公司，专注于开发药物，以治疗由异常升高的醛固酮引起的疾病。该公司的候选产品氯隆前列素是一种专有的口服高选择性醛固酮合酶抑制剂（ASI），该公司最初开发用于治疗未控制的高血压（uHTN）患者，定义为尽管服用了两种或多种抗高血压药物或抵抗性高血压（rHTN），但血压仍不能达到130/80mmHg以下的个体。在美国，有超过1.15亿患者患有持续性高血压（BP）或高血压，超过一半的患者未能实现血压目标，即目前可用的药物血压为130/80 mmHg。超过3000万接受治疗的患者没有达到血压目标，其中约2000万患者的收缩压水平超过140 mmHg。尽管服用了两种或两种以上药物，但高血压患者仍持续存在，心血管疾病或中风导致的死亡率风险分别为1.8倍和2.5倍。在一项评估200名uHTN和rHTN（目标HTN）受试者的第2阶段临床试验中，洛龙前列素显示，每天给药一次，血压下降具有临床意义和统计学意义，且耐受性良好。除高血压外，该公司还打算开发用于治疗慢性肾脏病（CKD）的氯前列素。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081442},{"month":3,"riseRate":0.25,"avgChangeRate":0.095856},{"month":4,"riseRate":0,"avgChangeRate":-0.078413},{"month":5,"riseRate":1,"avgChangeRate":0.100473},{"month":6,"riseRate":0.25,"avgChangeRate":-0.046559},{"month":7,"riseRate":0.75,"avgChangeRate":0.001731},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001437},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mineralys Therapeutics, Inc.(MLYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mineralys Therapeutics, Inc.(MLYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}